Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 10/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3800593 | 0.90 | PRMT6 (0.47) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL3802124 | 0.89 | P2RY12 (0.54) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL13020577 | 0.89 | PRMT6 (0.49) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL1070322 | 0.87 | PRMT6 (0.47) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL13020575 | 0.87 | MEN1 (0.50) | P2RY12PRMT6 | |
| SCHEMBL26112399 | 0.86 | PRMT6 (0.48) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL3801831 | 0.84 | PRMT6 (0.43) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL26653470 | 0.84 | PRMT6 (0.49) | P2RY12PRMT6 | |
| SCHEMBL23499895 | 0.83 | PRMT6 (0.49) | P2RY12P2RY2P2RY1P2RY6PRMT6 | |
| SCHEMBL26653893 | 0.83 | PRMT6 (0.49) | P2RY12P2RY2P2RY1P2RY6PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | RNASEL, RNASE1, RNASEH1 | P2RY12 4292/4885P2RY2 2712/4885P2RY1 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.